Today
-0.95%
5 Days
+1.07%
1 Month
-1.69%
6 Months
+40.50%
Year to Date
+21.93%
1 Year
+29.29%
• Danaher narrowed its full-year core revenue growth projections following second-quarter results. • Outgoing leadership announced a transition alongside subsequent disclosures of executive share sales. • The company reported latest annual revenue of $24.57B and net profit of $3.61B.
• ResMed faces volatility from Astral ventilator sales suspensions and strategic portfolio adjustments. • Management reports under-penetrated sleep apnea markets despite ongoing debate over GLP-1 therapies. • The company generated $5.65B in annual revenue with net profit reaching $1.52B.
• CVS Health gained following an institutional upgrade and strong earnings visibility. • Market rotation into defensive healthcare sectors supported buying interest amid broader volatility. • Annual revenue reached $402.07 billion with a net profit of $1.77 billion.
• Veeva reported strong second-quarter results and raised its full-year financial guidance. • Accelerated customer adoption and Vault CRM momentum drove double-digit revenue expansion. • Multiple analysts raised price targets following the upbeat earnings report.
• BrightSpring reported strong second-quarter revenue and raised its full-year guidance. • Wall Street analysts maintained buy ratings with an average price target of $78.97. • Annual revenue reached $12.91 billion with a net profit of $190.67 million.
• HCA Healthcare reported strong quarterly operating results driven by robust patient admissions. • Institutional accumulation and strategic outpatient expansion reinforced positive investor sentiment and price momentum. • The company achieved annual revenue of $75.60B and net profit of $6.78B.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.48% |
| BlackRock Institutional Trust Company, N.A. | 5.07% |
| State Street Investment Management (US) | 4.98% |
| Vanguard Portfolio Management, LLC | 2.65% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.13% |
| Investment Advisor/Hedge Fund | 26.02% |
| Research Firm | 3.63% |
| Pension Fund | 2.30% |
Related Instruments
Popular Instruments